Treace Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) has announced participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 am ET. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat. The event aims to highlight Treace's advancements in treating hallux valgus (bunions) through their patented Lapiplasty® 3D Bunion Correction™ system and the recently introduced Adductoplasty™ Midfoot Correction System, which addresses complex foot deformities and enhances patient recovery.

Positive

• Participation in a notable healthcare conference could increase visibility among investors.
• Showcasing proprietary technology like the Lapiplasty® system positions the company as an innovator in bunion treatment.
• The introduction of the Adductoplasty™ system suggests potential for expanded market reach and revenue growth.

Negative

• None.

PONTE VEDRA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, beginning at approximately 9:20 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot corrections. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system - a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com. 

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net 
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net 

FAQ

What date is Treace Medical Concepts participating in the Stifel 2021 Virtual Healthcare Conference?

Treace Medical Concepts will participate on November 15, 2021.

Who from Treace Medical Concepts will speak at the conference?

CEO John T. Treace and CFO Mark L. Hair will represent the company.

What innovative systems does Treace Medical Concepts offer for bunion treatment?

Treace offers the Lapiplasty® 3D Bunion Correction™ system and the Adductoplasty™ Midfoot Correction System.

Where can I find the webcast of Treace Medical Concepts' conference participation?

The webcast will be available on Treace's investor relations website.

What is Treace Medical Concepts' stock symbol?

The stock symbol for Treace Medical Concepts is TMCI.